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Introduction: Treatment with recombinant human erythropoietin (rHuEpo) is associated with an im-
provement in well-being and quality of life in patients submitted to maintenance hemodialysis (HD).
Objectives: The goal of this work was to evaluate the levels of sex hormones, hematocrit, albumin and
zinc in HD patients with rHuEpo therapy and compare them with those observed in patients without 
rHuEpo treatment. Material and methods: Two groups of twelve male HD patients each were selected for 
a transversal study; one did not receive rHuEpo (group 1) whereas the other one did (group 2). Levels of 
hematocrit, albumin, zinc, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, and
testosterone were determined. Results: Group 2 patients showed signiﬁcantly higher medians (p < 0.05)
of testosterone (4.65 vs. 3.5ng/mL), hematocrit (30.5 vs. 22%), albumin (3,9 vs. 3,7g/dL) and zinc (62.5
vs. 50.5microg/dL) than group 1 patients. Discussion: In this study rHuEpo treatment resulted in higher 
hematocrit, testosterone, zinc and albumin. It is suggested that, in patients recipients of rHuEpo, higher 
levels of zinc and testosterone may be factors that contribute to relieve sexual dysfunction and improve
quality of life. Conclusions: In HD patients, hematocrit, albumin, serum zinc and testosterone levels were








Introdução: Em pacientes submetidos à hemodiálise crônica (HD), o tratamento com eritropoetina humana 
recombinante (rHuEpo) está associado a melhora no bem-estar geral e na qualidade de vida. Objetivos: O 
objetivo do presente trabalho foi avaliar os níveis dos hormônios sexuais e do zinco em pacientes sob HD 
e em uso de rHuEpo em comparação com pacientes sem tratamento com essa droga. Material e métodos: 
Dois grupos de doze pacientes do sexo masculino cada um, submetidos à HD, sendo um deles sem uso de 
rHuEpo (grupo 1) e o outro utilizando a droga (grupo 2), foram selecionados para um estudo transversal,
comparando-se os níveis séricos do zinco, da albumina, dos hormônios FSH, LH, prolactina, testosterona e do 
hematócrito. Resultados: No grupo 2, os valores de testosterona (4,65 vs. 3,5ng/ml), hematócrito (30,5 vs.
22%), albumina (3,9 vs. 3,7g/dl) e zinco (62,5 vs. 50,5microg/dl) foram signiﬁcativamente maiores do que 
no grupo 1 (p < 0,05). Discussão: Sugere-se que, em pacientes recipientes da rHuEpo, os níveis mais altos de 
hematócrito, zinco, albumina e testosterona possam ser fatores que contribuam para melhorar a disfunção 
sexual e a qualidade de vida dos pacientes hemodialisados. Conclusão: Os pacientes em HD em uso da rHuEpo 
apresentaram níveis mais elevados de testosterona, zinco e hematócrito quando comparados com os pacientes 
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This transversal study was conducted at the dialysis 
center of the university hospital and included 24 patients on 
HD (four hours, three times a week). Patients were divided 
into two groups. Group 1(n = 12) consisted of patients that 
had not been in rHuEpo treatment for the last six months 
because during the study rHuEpo therapy was only available 
to patients enrolled in the transplant program. Patients in 
group 2 (n = 12) received rHuEpo regularly for six months, 
before the start of the study to obtain a target hematocrit 
of 32%-33%. Twelve healthy male subjects were included 
as a reference group for hormones and hematological 
parameters.
Patients with a history of alcohol ingestion, smoking, and 
use of antihypertensives and/or other drugs that interfere 
with the sexual function were excluded. Patients with 
depression or undergoing treatment with antidepressive 
drugs were also excluded. None of the patients in either 
group received blood transfusions during the study or in the 
preceding two weeks. Heparin was used as anticoagulant 
during hemodialysis, and a cellulose acetate dialyzing 
membrane was employed. All patients were on a diet 
consisting of 1g/kg/day of protein of high biological value. 
Calcium carbonate was prescribed with the meals (1.5-3g/
day) to keep serum phosphate levels below 5.5mg/dl and 
serum calcium levels below 10.5mg/dl.
Blood samples were withdrawn from all subjects at 7:00 
a.m. after overnight fasting and before the hemodialysis 
session. Disposable plastic syringes without rubber were 
used to avoid zinc contamination. Serum was separated 
from clotted blood by centrifugation with care to avoid 
hemolysis in zinc-free tubes. Serum was removed and 
stored at -20°C. Serum zinc concentration was determined 
by atomic absorption spectrophotometry (Perkin-Elmer, 
Norwalk, Conn, USA)(30).
Serum concentrations of hormones (testosterone, FSH, 
LH, and prolactin) were measured by double antibody 
radioimmunoassay (Kit Coat-A-Count, Diagnostic Products 
Corporation, Los Angeles, CA, USA). Albumin was 
determined using autoanalyser, and hematocrit, by the 
automatized method used at Brasília’s University Hospital.
Statistical analysis
Because of the small number of subjects and non-normal 
distribution of other variables evaluated, the data were 
analyzed employing non-parametric statistics. Continuous 
variables in the three groups were simultaneously compared 
using Kruskal-Wallis test followed by Student-Newman-
Introduction
Hemodialysis (HD) technique has gradually improved 
over the last few decades, providing a more effective 
and safer treatment and resulting in better quality of 
life for end-stage renal disease (ESRD) patients. Modern 
technology with volumetric control of ultra-ﬁltration, 
improvement in biocompatible membranes and control 
of dialysis doses, as well as treatment of anemia with 
recombinant human erythropoietin (rHuEpo), have 
contributed to decrease co-morbidity in HD(13, 19). Despite 
improvements, hormonal dysfunction is common in 
uremic patients, and the associated impaired function of 
the hypothalamic-pituitary-gonadal axis is not reversed 
by dialysis therapy. Erectile dysfunction, decreased libido, 
low frequency of intercourse, oligo- or azoospermia, and 
gynecomastia are common problems among male uremic 
patients. These symptoms are very distressing and can 
seriously damage patient’s self-esteem, causing anxiety 
and possibly affecting outcome. The origin of this disorder 
is multifactorial, yet its precise mechanism remains unclear. 
Its cause in ESRD patients undergoing chronic dialysis has 
been related to decreased testosterone, higher follicle-
stimulating hormone (FSH) and luteinizing hormone 
(LH) levels (hypergonadotropic hypogonadism), higher 
prolactin, impaired function of the hypothalamic-pituitary-
gonadal axis, zinc deﬁciency, anemia, and vascular and 
neurological complications(21).
The use of rHuEpo therapy appears to relieve sexual 
dysfunction(2) and to increase serum testosterone levels in 
uremic patients(33). These effects are probably the result of 
anemia correction, improvement in nutritional status and/or 
a direct metabolic action of rHuEpo(21).
Objectives
The objective of this study was to evaluate hormonal 
proﬁle, hematocrit, serum zinc, and albumin levels in HD 
patients as a function of rHuEpo therapy. Therefore, a 
transversal study was proposed, including two groups of 
HD patients; one group received rHuEpo therapy and the 
other one did not.
Material and methods
The ethics committee of the Universidade de Brasília’s 
Hospital approved the study, and patients gave written 
informed consent to participate.
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Keuls test for multiple comparisons between pairs of 
groups. Age and months on dialysis in patients submitted 
to hemodialysis were compared using Mann-Whitney rank 
sum test. The correlation between zinc and other laboratory 
variables was studied using Spearman rank correlation 
coefﬁcient (rs). Statistical signiﬁcance level of differences 
for all comparisons was set at 5% (p < 0.05). Data analysis 
was done with SigmaStat® (Jandel Scientiﬁc, USA, 1993) 
software package.
Results
For the subjects enrolled in this study, demographic 
characteristics, months on dialysis and etiology of end-stage 
renal failure are shown in Table 1. There were no signiﬁcant 
differences for age and time on dialysis between the two 
groups studied.
Median (range) of zinc, hormones, albumin and hematocrit







Zinc (microg/dL) 86.5 (65-95) 50.5(42-67)+ 62.5 (52-82)#+ < 0.05
Testosterone (ng/mL) 7.5 (5-10) 3.5 (1.5-5.2)+ 4.6 (3.5-4.6)#+ < 0.05
Prolactin (ng/mL) 9.5 (7.5-15.5) 19.2 (10-46)+ 23.1 (10.5-47)+ < 0.05
FSH (mUI/mL) 8.7 (6-16.8) 10.2 (2-56) 14.5 (4-36) > 0.05
LH (mUI/mL) 2.7 (1.9-3.6) 3.1 (1.8-10.3) 3.6 (2.6-9.2) > 0.05
Albumin (g/dL) 4 (3.7-4.3) 3.7 (2.7-4)+ 3.9 (3.3-4.3) < 0.05
Hematocrit (%) 43.5 (40-47) 22 (16-25)+ 30.5 (27-33)#+ < 0.05
*p value for simultaneous comparison between the three groups by means of the Kruskal-Wallis test; #signiﬁcant difference (p < 0.05) between treated and non-treated patient 
groups; +signiﬁcant difference (p < 0.05) between treated or non-treated patient groups and the control group.
Demographics, months on dialysis, and causes of renal failure of the subjects studied
Variable Reference subjects Non-treated patients Treated patients p**
Age (years)* 40 (19-50) 40 (19-51) 40.5 (19-51) 0.862
Sex (male/female ratio) 12/0 12/0 12/0 -
Race (white/black ratio) 7/5 7/5 6/6 -
Months on dialysis* - 33 (8-64) 36 (9-54) 0.954
Chronic glomerulonephritis - 5 4 -
Hypertensive nephrosclerosis - 4 4 -
Polycystic renal disease - - 1 -
Chronic interstitial nephritis - 1 1 -
Indeterminate causes - 2 2 -
*Values shown are median (range); **p value for comparison between the treated and non-treated patient groups by means the Mann-Whitney rank sum test.
Tabelale 1
Tabelale 2
A summary of results of laboratory variables is shown 
in Table 2. Patients of group 1 had lower median serum 
testosterone levels than rHuEpo-treated group (p < 0.05). 
However, median serum testosterone was signiﬁcantly 
lower in patients of both groups than in healthy reference 
subjects (p < 0.05, Kruskall-Wallis). There was no statistically 
signiﬁcant difference for serum prolactin between the two 
groups, but patients of both groups showed a signiﬁcantly 
higher median serum prolactin than respective values for 
reference subjects (p < 0.05). Despite a higher median 
of serum FSH and LH levels in HD patients, there was no 
statistically signiﬁcant difference when they were compared 
with reference subjects.
Serum albumin from groups 1 and 2 patients was 
signiﬁcantly lower than the respective values of reference 
subjects and was significantly lower in patients from 
group 1 than that observed in group 2 (p < 0,05). Patients 
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receiving rHuEpo (group 2) had signiﬁcantly higher serum 
zinc concentrations than group 1. However, serum zinc of 
reference subjects was signiﬁcantly higher than that in both 
hemodialysis groups (p < 0.05). As expected, hematocrit 
levels were lower in non-treated patients as compared to 
rHuEpo recipients. Nevertheless, both hemodialysis groups 
had lower hematocrit than reference subjects (p < 0.05).
In HD subjects, we observed a positive correlation 
between zinc and albumin (rs = 0.502, p = 0.012) and 
between zinc and hematocrit (rs = 0.553, p = 0.005). 
There were no signiﬁcant correlations between zinc and 
testosterone (rs = 0.395, p = 0.055) and zinc and prolactin 
(rs = - 0.286, p = 0.173).
Discussion
This transversal study was possible because there was a 
group of male HD patients who, voluntarily, did not enroll 
in the transplant program of the University Hospital and, 
during a period of six months, did not have access to rHuEpo 
because at the time of the study the drug was temporarily 
restricted to patients listed for transplant. Another group 
of male HD patients in use of rHuEpo and comparable in 
terms of age, causes of end stage renal disease, and dialysis 
length was enrolled.
Hormonal profile
Our results showed that rHuEpo-treated patients 
exhibited higher hematocrit, testosterone, and zinc levels. 
Indeed, patients treated with rHuEpo showed enhanced 
levels of testosterone and non-signiﬁcant differences in LH 
and FSH levels in relation to untreated subjects.
The administration of rHuEpo to patients with 
chronic renal failure seems to alter pituitary gonadal 
feedback mechanism with reduced plasma concentration 
of LH and FSH, and to increase plasma testosterone 
levels(15, 26). However, this effect of rHuEpo on patients 
undergoing hemodialysis was not uniformly present(3, 16, 
32). Plasma concentration of LH was elevated in patients on 
maintenance hemodialysis, and the increase is thought to 
result from diminished release of testosterone from Leydig 
cells and decreased LH renal clearance(18). FSH levels also 
increased, but less consistently. The moderate response of 
LH to low levels of testosterone suggests a dysfunction in 
the pituitary gonadal axis as demonstrated in hemodialized 
subjects(17, 27, 29). Although our patients showed higher 
LH and FSH values, there was no signiﬁcant difference in 
relation to reference subjects, which may be due to the great 
variability and small number of subjects. Indeed, the lack 
of signiﬁcant differences in LH and FSH between treated 
and non treated patients suggests that rHuEpo may have 
a direct effect or may act as a paracrine factor stimulating 
steroidogenesis in Leydig cells(6, 34).
Improvement of sexual function after rHuEpo treatment 
was attributed to normalization of elevated prolactin 
concentrations(28), but has not yet been conﬁrmed(2, 15).
Patients in dialysis complaining of sexual dysfunction after 
correction of anemia with rHuEpo were characterized by 
higher levels of serum testosterone, but not by suppression 
of hyperprolactinemia or hyperestrogenism(16). We observed 
that the median serum prolactin was high in both HD groups 
with lack of a signiﬁcant difference between them.
Zinc
In rHuEpo-treated patients, we observed signiﬁcantly 
higher levels of zinc than in non-treated patients, which is 
in agreement with other works(10, 11) It has been observed 
that in rHuEpo recipients zinc erythrocytes levels and 
serum albumin were signiﬁcantly higher than in patients 
without rHuEpo therapy(23), suggesting that rHuEpo use in 
HD may signiﬁcantly improve protein nutritional status, as 
well as the disturbance in zinc metabolism. These effects 
of rHuEpo in serum zinc have not always been reported(14).
Zinc deﬁciency has also been related to gonadal failure in 
chronic renal diseases(20) and in HD patients. This can be 
due to reduced dietary intake, zinc malabsorption, and/or 
possible leaching of zinc through the dialysis membrane(9, 
22). Indeed, the administration of supplemental zinc to HD 
patients resulted in increase in plasma testosterone and sperm 
count and decline in LH and FSH levels(20), effects that were 
not observed by other authors(1, 31, 35). Furthermore, zinc 
deﬁciency in rats and in humans may be associated with 
disturbance in testicular function and Leydig cell failure(8, 
12), even though experimental work showed that zinc 
concentrations in testis were signiﬁcantly higher in uremic 
compared to non-uremic sham-operated rats(25). However, 
a strong negative correlation between leukocyte-zinc and 
serum prolactin suggested that depletion of total zinc stores 
could be an important mechanism of hyperprolactinemia in 
uremic patients(5), although we did not observe a signiﬁcant 
correlation between serum prolactin and serum zinc. This is 
in agreement with previous reports in dialysis subjects(4, 24).
The importance of zinc deﬁciency in uremia and its 
role on physiopathology of hormonal dysfunction remains 
poorly understood. Moreover, only a small part of the total 
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body zinc content is in the blood, and serum zinc may not 
reﬂect the exact amount of zinc stores in uremic patients 
submitted to chronic dialysis. A difference in concentrations 
of this trace element between plasma, erythrocytes, and 
whole blood was observed(36). Despite that, serum zinc 
may be considered a marker of nutritional status in dialysis 
patients and it was positively correlated with pre-albumin, a 
useful marker of nutritional status(7). Higher levels of zinc in 
patients treated with rHuEpo were possibly related to well-
being and appetite improvements, and a better nutritional 
status that resulted from anemia correction.
In conclusion, patients treated with rHuEpo showed, in 
association with improvement of anemia, higher levels of 
serum zinc, albumin and testosterone.
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